This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Neuropathic Pain
and you are
between 18 and 85
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Primary Objective: To assess the efficacy of SAR292833 versus placebo in reducing pain intensity associated with chronic peripheral neuropathic pain using 11-point numerical rating scale (NRS). Secondary Objectives: - To compare the effects of SAR292833 with placebo on the change of neuropathic pain symptoms versus baseline Neuropathic Pain Symptoms Inventory (NPSI); - To evaluate the effects of SAR292833 in comparison to placebo on the change in pain intensity of mechanical allodynia; - To investigate the safety and tolerability of SAR292833 in comparison to placebo; - To investigate the pharmacokinetics (PK) and the relationships between main efficacy parameters or pharmacodynamic effect (PD) and pharmacokinetics (PK/PD) of SAR292833 in patients with chronic peripheral neuropathic pain.

Provided treatments

  • Drug: SAR292833
  • Drug: placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01463397. The sponsor of the trial is Sanofi and it is looking for 191 volunteers for the current phase.
Official trial title:
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain